Some notes on mesalazine treatment in patients with ulcerative colitis and Crohn‘s disease

Česká verzia

Authors: Lukáš M.
Authors place of work: Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze
Published in the journal: Gastroent Hepatol 2022; 76(3): 248-249
Category:
doi: https://doi.org/10.48095/ccgh2022248

Bortlík M, Duricová D, Hrdlička L et al. Doporučení PS-IBD pro diagnostiku a medikamentózní léčbu ulcerózní kolitidy. Gastroent Hepatol 2022; 76(1): 13–28. doi: 10.48095/ ccgh202213.
Leifeld L, Pfützer R, Morgenstem HJ et al. Mesalazine granules are supperior to Eudragit L couted mesalazine tabletsfor induction of remission in distal ulcerative colitis – a pooled analysis. Aliment Pharmacol Ther 2011; 34(2): 1115–1122. doi: 10.1111/ j.1365-2036.2011.04840.x.
Mantzaris G, Archavlis E, Christidou A et al. Mesalazine has no place in the treatment of Crohn’s disease. Really? ECCO 2022: P429.
Ben Horin S, Har-Noy O, Katsanos KH et al. Combination of corticosteroids with aminosalicylic acid versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: a multicenter randomized controlled trial. ECCO 2022: P 312.
Mahmoud R, Savelkoul E, Mares W et al. Anti-TNF withdrawal to a risk stratified protocol does not reduce risk of relapse in patients with IBD in endoscopic remisison. A prospective study. ECCO 2022: DOP70.
Rowan RC, Cullen G, Mulcahy ES et al. Dublin (Degree of Ulcerative Colitis Burden of Luminal Inflammation) score, a simple method to quantify inflammatory burden in ulcerative colitis. J Crohns Colitis J 2019; 13(11): 1365–1371. doi: 10.1093/ ecco-jcc/ jjz067.